Therapeutic Agent	Description	Clinical Trials	Phase of Investigation 1 2 3
INVESTIGATIONAL PRODUCT CANDIDATES			
Erlotinib tablets[a]	HER1/EGFR tyrosine kinase inhibitor	Adjuvant NSCLC Ovarian and colorectal cancers Other indications	3 3 2
MDV3100[b]	Triple-acting, oral androgen receptor antagonist	Advanced prostate cancer	3
OSI-906[a]	Selective small molecule, dual IGF-1R and IR tyrosine kinase inhibitor	Adrenocortical carcinoma (ACC) Ovarian cancer, NSCLC and advanced HCC	3 2
AC220[c]	Potent and selective, small molecule, FLT3 tyrosine kinase inhibitor (TK)	Relapsed and refractory AML	2
AGS-1C4D4	Fully human monoclonal antibody to prostate stem cell antigen (PSCA)	Metastatic pancreatic cancer	2
YM155	Small molecule survivin suppressant	B-cell NHL, metastatic breast cancer, and malignant melanoma	2
OSI-027[a]	mTOR kinase inhibitor with dual inhibitory activity to both TORC1 and TORC2 complexes	Advanced solid tumors and lymphomas	1
AGS-16M8F	Fully human monoclonal antibody drug conjugate (ADC) to AGS-16, a novel transmembrane protein expressed in certain tumors	Advanced renal cell carcinoma	1
ASG-5ME[d]	Fully human antibody drug conjugate to ASG-5, a novel transmembrane protein expressed in certain tumors	Pancreatic andenocarcinoma	1
ASP3026	ALK tyrosine kinase inhibitor"	cancer	1

[a] OSI [b] Medivation [c] Ambit [d] Agensys, co-development with Seattle Genetics